John David Clemens

John David Clemens

Auto-generated profile, based on publicly available information

John David Clemens

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; International Vaccine Institute, Seoul, Republic of Korea; UCLA Fielding, School of Public Health, Los Angeles, CA 90095-1772, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in The Lancet
Verified
Journal Article
Closed access
JCJohn D Clemens
John D Clemens
GNG Balakrish Nair
G Balakrish Nair
TATahmeed Ahmed
Tahmeed Ahmed
FQFirdausi Qadri
Firdausi Qadri
JHJan Holmgren
Jan Holmgren

1 May 2021 in The Lancet Global Health
Verified
Journal Article
Open access
EFEric Finkelstein
Eric Finkelstein
AKAnirudh Krishnan
Anirudh Krishnan
ANAliya Naheed
Aliya Naheed
IJImtiaz Jehan
Imtiaz Jehan
HSH Asita de Silva
H Asita de Silva
STSay Beng Tan
Say Beng Tan
COBRA-BPS (Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka), a multi-component hypertension management programme that is led by community health workers, has been shown to be efficacious at reducing systolic blood pressure in rural communities in Bangladesh, Pakistan, and Sri Lanka. In this study, we aimed to assess the budget required to scale up the programme and the incremental cost-effectiveness ratios. In a cluster-randomised trial of COBRA-BPS, individuals aged 40 years or older with hypertension who lived in 30 rural communities in Bangladesh, Pakistan, and Sri Lanka were deemed eligible for inclusion. Costs were quantified prospectively at baseline and during 2 years of the trial. All costs, including labour, rental, materials and supplies, and contracted services were recorded, stratified by programme activity. Incremental costs of scaling up COBRA-BPS to all eligible adults in areas covered by community health workers were estimated from the health ministry (public payer) perspective. Between April 1, 2016, and Feb 28, 2017, 11 510 individuals were screened and 2645 were enrolled and included in the study. Participants were examined between May 8, 2016, and March 31, 2019. The first-year per-participant costs for COBRA-BPS were US$10·65 for Bangladesh, $10·25 for Pakistan, and $6·42 for Sri Lanka. Per-capita costs were $0·63 for Bangladesh, $0·29 for Pakistan, and $1·03 for Sri Lanka. Incremental cost-effectiveness ratios were $3430 for Bangladesh, $2270 for Pakistan, and $4080 for Sri Lanka, per cardiovascular disability-adjusted life year averted, which showed COBRA-BPS to be cost-effective in all three countries relative to the WHO-CHOICE threshold of three times gross domestic product per capita in each country. Using this threshold, the cost-effectiveness acceptability curves predicted that the probability of COBRA-BPS being cost-effective is 79·3% in Bangladesh, 85·2% in Pakistan, and 99·8% in Sri Lanka. The low cost of scale-up and the cost-effectiveness of COBRA-BPS suggest that this programme is a viable strategy for responding to the growing cardiovascular disease epidemic in rural communities in low-income and middle-income countries where community health workers are present, and that it should qualify as a priority intervention across rural settings in south Asia and in other countries with similar demographics and health systems to those examined in this study. The UK Department of Health and Social Care, the UK Department for International Development, the Global Challenges Research Fund, the UK Medical Research Council, Wellcome Trust.

1 September 2014 in Vaccine
Verified
Journal Article
Closed access
JUJasim Uddin
Jasim Uddin
TWTasnuva Wahed
Tasnuva Wahed
NSNirod Chandra Saha
Nirod Chandra Saha
SKSheikh Shah Tanvir Kaukab
Sheikh Shah Tanvir Kaukab
IKIqbal Ansary Khan
Iqbal Ansary Khan
FQFirdausi Qadri
Firdausi Qadri

4 January 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AAAfroza Akter
Afroza Akter
TATasnuva Ahmed
Tasnuva Ahmed
ITImam Tauheed
Imam Tauheed
MAMarjahan Akhtar
Marjahan Akhtar
SRSadia Isfat Ara Rahman
Sadia Isfat Ara Rahman
FQFirdausi Qadri
Firdausi Qadri
Background: COVID-19 caused by SARS-CoV-2 ranges from asymptomatic to severe disease and can cause fatal and devastating outcome in many cases. In this study, we have compared the clinical, biochemical and immunological parameters across the different disease spectrum of COVID-19 in Bangladeshi patients. Methodology/Principal findings: This longitudinal study was conducted in two COVID-19 hospitals and also around the community in Dhaka city in Bangladesh between November 2020 to March 2021. A total of 100 patients with COVID-19 infection were enrolled and classified into asymptomatic, mild, moderate and severe cases (n = 25/group). In addition, thirty age and sex matched healthy participants were enrolled and 21 were analyzed as controls based on exclusion criteria. After enrollment (study day1), follow-up visits were conducted on day 7, 14 and 28 for the cases. Older age, male gender and co-morbid conditions were the risk factors for severe COVID-19 disease. Those with moderate and severe cases of infection had low lymphocyte counts, high neutrophil counts along with a higher neutrophil-lymphocyte ratio (NLR) at enrollment; this decreased to normal range within 42 days after the onset of symptom. At enrollment, D-dimer, CRP and ferritin levels were elevated among moderate and severe cases. The mild, moderate, and severe cases were seropositive for IgG antibody by day 14 after enrollment. Moderate and severe cases showed significantly higher IgM and IgG levels of antibodies to SARS-CoV-2 compared to mild and asymptomatic cases. Conclusion/Significance: We report on the clinical, biochemical, and hematological parameters associated with the different severity of COVID-19 infection. We also show different profile of antibody response against SARS-CoV-2 in relation to disease severity, especially in those with moderate and severe disease manifestations compared to the mild and asymptomatic infection.


13 April 2023 in Vaccine
Verified
Journal Article
Open access
FKFarhana Khanam
Farhana Khanam
GBGolap Babu
Golap Babu
NRNazia Rahman
Nazia Rahman
XLXinxue Liu
Xinxue Liu
NRNazmul Hasan Rajib
Nazmul Hasan Rajib
FQFirdausi Qadri
Firdausi Qadri
A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.